← Leaderboards
Binghe Wang
North Carolina State University Raleigh
$7,208,661
Attributed
$13,945,432
Total exposure
11
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.5M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$13,945,432 · 11
By mechanism
R01$11,380,362 · 5
R21$1,011,052 · 3
R42$555,098 · 1
R33$554,920 · 1
R56$444,000 · 1
Top collaborators
- Leo E Otterbein9 shared
- Chalet Tan5 shared
- Muxiang Zhou5 shared
- Mark P De Caestecker4 shared
- Hans E Grossniklaus3 shared
- Erwin G Van Meir3 shared
- Zehava Eichenbaum1 shared
- Phang C. Tai1 shared
Others in their field
Top investigators on “Base”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$613,567,095
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Larry Arthur$521,411,998
- Leonard Freedman · Leidos Biomedical Research, Inc.$515,995,429
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$507,042,060
Research focus
BasePropertyLeadFutureAnimal ModelMouse ModelInterestDesignReportingBiologicalFoundationsMalignant NeoplasmsAnimalsPre-ClinicalPreventPharmacologyPharmaceutical ChemistryChemistryTherapeutic AgentsCarbohydratesLiverPharmacologic SubstancePreparationBinding (Molecular Function)
Grant awards (34)
Early-Stage Preclinical Validation of Carbon Monoxide Prodrugs for Acute Kidney Injury$705,716
R01 · FY2025 · DK · contact PI
Early-Stage Preclinical Validation of Carbon Monoxide Prodrugs for Acute Kidney Injury$678,976
R01 · FY2024 · DK · contact PI
Examining Carbon Monoxide to Treat Inflammatory Conditions using Experimental Colitis Models$708,873
R01 · FY2023 · DK · contact PI
Early-Stage Preclinical Validation of Carbon Monoxide Prodrugs for Acute Kidney Injury$707,586
R01 · FY2023 · DK · contact PI
Early-Stage Preclinical Validation of Carbon Monoxide Prodrugs for Acute Kidney Injury$750,347
R01 · FY2022 · DK · contact PI
Examining Carbon Monoxide to Treat Inflammatory Conditions using Experimental Colitis Models$708,873
R01 · FY2022 · DK · contact PI
Examining Carbon Monoxide to Treat Inflammatory Conditions using Experimental Colitis Models$708,873
R01 · FY2021 · DK · contact PI
Examining Carbon Monoxide to Treat Inflammatory Conditions using Experimental Colitis Models$707,948
R01 · FY2020 · DK · contact PI
Examining Carbon Monoxide to Treat Inflammatory Conditions using Experimental Colitis Models$733,350
R01 · FY2019 · DK · contact PI
Novel anthraquinones induce apoptosis by disruption MDM2/MDM4 interactions$442,311
R01 · FY2018 · CA · contact PI
Novel anthraquinones induce apoptosis by disruption MDM2/MDM4 interactions$442,311
R01 · FY2017 · CA · contact PI
Novel anthraquinones induce apoptosis by disruption MDM2/MDM4 interactions$442,311
R01 · FY2016 · CA · contact PI
Discovery of chemical probes for uveal melanoma$564,926
R01 · FY2015 · CA
Novel anthraquinones induce apoptosis by disruption MDM2/MDM4 interactions$442,311
R01 · FY2015 · CA · contact PI
Discovery of chemical probes for uveal melanoma$558,016
R01 · FY2014 · CA
Novel anthraquinones induce apoptosis by disruption MDM2/MDM4 interactions$460,311
R01 · FY2014 · CA · contact PI
Examining SecA as a Potential Target for Treating Gram-positive Bacteria$444,000
R56 · FY2014 · AI · contact PI
Discovery of chemical probes for uveal melanoma$455,506
R01 · FY2013 · CA
Selection of Boronic Acid-modified Aptamers for Glycoproteins$284,621
R01 · FY2011 · GM · contact PI
Selection of Boronic Acid-modified Aptamers for Glycoproteins$287,496
R01 · FY2010 · GM · contact PI
Aptamer-based Glycomics Tools$277,549
R42 · FY2010 · GM · contact PI
Selection of Boronic Acid-modified Aptamers for Glycoproteins$290,400
R01 · FY2009 · GM · contact PI
Aptamer-based Glycomics Tools$277,549
R42 · FY2009 · GM · contact PI
Selection of Boronic Acid-modified Aptamers for Glycoproteins$299,300
R01 · FY2008 · GM · contact PI
MRI contrast agents targeting carbohydrate biomarkers$191,057
R21 · FY2007 · CA · contact PI
MRI contrast agents targeting carbohydrate biomarkers$165,610
R21 · FY2006 · CA · contact PI
Fluorescent Aptamers for Glycoprotein Detection$141,104
R21 · FY2006 · CA · contact PI
Fluorescent Aptamers for Glycoprotein Detection$40,185
R21 · FY2006 · CA · contact PI
Fluorescent Aptamers for Glycoprotein Detection$145,500
R21 · FY2005 · CA
Fluorescent Aptamers for Glycoprotein Detection$39,285
R21 · FY2005 · CA
FLUORESCENT TAGS TARGETED ON CELL SURFACE CARBOHYDRATES$288,000
R33 · FY2003 · CA
FLUORESCENT TAGS TARGETED ON CELL SURFACE CARBOHYDRATES$266,920
R33 · FY2002 · CA
FLUORESCENT TAGS TARGETED ON CELL SURFACE CARBOHYDRATES$140,267
R21 · FY2001 · CA
FLUORESCENT TAGS TARGETED ON CELL SURFACE CARBOHYDRATES$148,044
R21 · FY2000 · CA